DEF 14A: Centene Corporation Outlines Strategy for Growth and Sustainability in 2024 Proxy Statement

Centene Corporation's 2024 proxy statement highlights the company's strategic advancements, financial performance, and commitment to sustainability and corporate governance.

Summary

• Centene Corporation's proxy statement details the company's performance in 2023, highlighting strategic and operational advancements.
• The company reported $4.95 of diluted earnings per share (EPS) and $6.68 of adjusted diluted EPS for full year 2023, increases of over 139% and 15%, respectively, compared to full year 2022.
• Medicaid membership stands at 14.5 million across 30 states, Marketplace membership grew to 3.9 million, and Medicare Advantage membership is at 1.3 million across 36 states.
• Centene has completed 10 divestitures over two years to focus on core businesses.
• The company is committed to sustainability, focusing on empowering health, building healthier communities, fostering a healthy environment, and driving business accountability.
• The Board of Directors has made significant refreshments, with an average tenure of less than 5 years.
• Stockholders will vote on the election of ten directors, an advisory resolution on executive compensation, and the ratification of KPMG LLP as the independent registered public accounting firm.
• The company emphasizes its commitment to good governance, including annual election of directors, majority voting, and proxy access rights for stockholders.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both achievements and challenges. The positive financial results and strategic advancements contribute to a moderately positive sentiment, tempered by the stock price decline and unmet goals.

Positives

• Centene achieved significant growth in Marketplace membership, indicating successful expansion and value creation.
• Medicare Advantage quality scores improved, with a substantial increase in membership associated with contracts rated 3.0 Stars or better.
• The company's focus on dual eligibles in Medicare Advantage positions it well to serve this critical population.
• Divestitures have allowed Centene to streamline operations and focus on core businesses.
• Centene's commitment to diversity and inclusion is reflected in its workforce composition.
• The Board is actively engaged in improving corporate governance practices based on stockholder feedback.

Negatives

• The company's stock price declined 9.5% in 2023, underperforming the S&P 500 index.
• The company did not meet expected revenue equivalent to 40% of Medicare membership in 4+ Star plan target.
• The company was unsuccessful in renewing the New Mexico Medicaid contract and did not win a new Indiana managed long-term services and support contract.

Risks

• The dynamic healthcare landscape requires Centene to demonstrate operational agility and resilience.
• The company is navigating through the unprecedented Medicaid redetermination process.
• Climate change could reduce the ability to accurately predict and effectively control the costs of providing health benefits.
• The company is subject to multiple laws and regulations governing GHG emissions and related disclosure requirements.

Future Outlook

Centene plans to harness growth opportunities in commercial markets, serve existing and new state partners, and address the expanding population of dual-eligible Americans.

Management Comments

• The dynamic healthcare landscape continues to offer Centene opportunities to demonstrate our operational agility and resilience.
• Our uniquely local approach informs our ongoing development of new and innovative ways to serve our members and customers while strengthening our foundational core operations.
• We are focused on fortifying our platform and expanding our business as the dynamic healthcare landscape continues to evolve.
• It is a privilege to serve our members each and every day, and we remain committed in all that we do to transform the health of the communities we serve, one person at a time.

Industry Context

Centene is positioned as a leader in government-sponsored healthcare, focusing on low-income, complex populations, and competing with other major players in the Medicaid, Marketplace, and Medicare sectors.

Comparison to Industry Standards

• Centene compares itself to Cigna, Elevance Health, Humana, Molina Healthcare, and UnitedHealth Group in the managed health care sector.
• The company also benchmarks against Cencora, Cardinal Health, McKesson Corporation, CVS Health Corporation, Walgreens Boots Alliance, and HCA Healthcare, Inc.
• Centene's market capitalization and revenue are in the 31st percentile relative to its peer group.

Related Party Transactions

• Centene has continued to pay LifeStance for behavioral health services provided by LifeStance to the Company's health plans in accordance with contracts entered into between the companies prior to Mr. Burdick's employment with LifeStance.
• In 2023, one of our executive officers had a related party employed by the Company who earned total compensation above $120,000. The employee's compensation and benefits were consistent with total compensation and benefits provided to other employees of the same level with similar responsibilities.

Stakeholder Impact

• The company's performance and strategic decisions impact shareholders, members, providers, employees, and government partners.
• Centene's commitment to sustainability and community involvement aims to improve the health and well-being of the communities it serves.

Next Steps

• Stockholders will vote on the election of directors, executive compensation, and the ratification of the independent auditor at the Annual Meeting on May 14, 2024.
• The company will continue to engage with stockholders regarding environmental progress and the adoption of GHG reduction targets.
• The company will continue to monitor regulatory proposals and prioritize resources and efforts appropriately.

Key Dates

Keywords

Centene, governance, Medicaid, Medicare, Marketplace, sustainability, executive compensation, directors, EPS, divestitures